Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
Carfilzomib
PTCL
Phase 1 trial
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
25
09
2021
accepted:
30
09
2021
pubmed:
21
10
2021
medline:
21
1
2022
entrez:
20
10
2021
Statut:
ppublish
Résumé
Peripheral T-cell lymphomas (PTCL) are a unique subset of lymphomas with a poor prognosis due to limited treatment options. We performed a phase 1 study of carfilzomib in patients with relapsed/refractory PTCL to determine the safety profile and the maximum tolerated dose (MTD) of this agent. The study was a classical 3 + 3 phase 1 design with intra-patient dose escalation allowed beginning on day 8 of cycle 1 and subsequently. Dose-limiting toxicity (DLT) was defined as the occurrence of any grade 3/4 adverse event. Carfilzomib was given on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Fifteen patients were enrolled from 3 centers. The median age of patients was 62. The median number of prior therapies for subjects on this trial was five. The MTD of carfilzomib was 36 mg/m
Identifiants
pubmed: 34668982
doi: 10.1007/s00277-021-04692-9
pii: 10.1007/s00277-021-04692-9
doi:
Substances chimiques
Antineoplastic Agents
0
Oligopeptides
0
carfilzomib
72X6E3J5AR
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
335-340Informations de copyright
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263(5151):1281–1284
doi: 10.1126/science.8122112
Tsukasaki K, Tsushima H, Yamamura M, Hata T, Murata K, Maeda T et al (1997) Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease. Blood 89(3):948–956
doi: 10.1182/blood.V89.3.948
Rüdiger T, Geissinger E, Müller-Hermelink HK (2006) ‘Normal counterparts’ of nodal peripheral T-cell lymphoma. Hematol Oncol 24(4):175–180
doi: 10.1002/hon.786
Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24(16):2472–2479
doi: 10.1200/JCO.2005.03.6327
Vose JM, Weisenburger DD, Armitage JO et al (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130
doi: 10.1200/JCO.2008.16.4558
Martinez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J et al (2005) Differential expression of NF-κB pathway genes among peripheral T-cell lymphomas. Leukemia 19(12):2254
doi: 10.1038/sj.leu.2403960
de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109(11):4952–4963
doi: 10.1182/blood-2006-10-055145
Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S et al (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67(22):10703–10710
doi: 10.1158/0008-5472.CAN-07-1708
MLAPiccaluga Pier-Paolo, et al. (2005) “Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.” 1217–1217
Cuadros M, Dave SS, Jaffe ES, Honrado E, Milne R, Alves J et al (2007) Identification of a proliferation signature related to survival in nodal peripheral T-cell lymphomas. J Clin Oncol 25(22):3321–3329
doi: 10.1200/JCO.2006.09.4474
Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115(5):1026–1036
doi: 10.1182/blood-2009-06-227579
Iqbal J, d’Amore F, Hu Q, Chan WC, Fu K (2006) Gene arrays in lymphoma: where will they fit in? Curr Hematol Malig Rep 1(2):129–136
doi: 10.1007/s11899-006-0024-5
Horwitz S, O’Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229–240
doi: 10.1016/S0140-6736(18)32984-2
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120(14):2817–2825
doi: 10.1182/blood-2012-05-425934
Piccaluga PP, Agostinelli C, Califano A, Rossi M, Basso K, Zupo S et al (2007) Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 117(3):823–834
doi: 10.1172/JCI26833
Papadopoulos KP, Burris HA, Gordon M, Lee P, Sausville EA, Rosen PJ, Patnaik A, Cutler RE, Wang Z, Lee S, Jones SF (2013) A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol 72(4):861–868
doi: 10.1007/s00280-013-2267-x
Iqbal J, d’Amore F, Hu Q, Chan WC, Fu K (2006) Gene arrays in lymphoma: where will they fit in? Curr Hematol Malig Rep 1(2):129–136
doi: 10.1007/s11899-006-0024-5
Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho A et al (2010) Treatment and prognosis of nature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-hodgkin lymphoma study group. Blood 116:3418–3425
doi: 10.1182/blood-2010-02-270785
Wang ES, O’Connor O, She Y, Zelenetz AD, Sirotnak F, Moore MA (2003) Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44(6):1027–1035
doi: 10.1080/1042819031000077124
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22):5827–5834
doi: 10.1182/blood-2010-10-312603
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA et al (2014) Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123(20):3095–3100
doi: 10.1182/blood-2013-12-542142
O’Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J et al (2015) Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol 33(23):2492–2499
doi: 10.1200/JCO.2014.59.2782
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E et al (2018) A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood 131:397–407
doi: 10.1182/blood-2017-09-806737
Mehta-Shah N, Moskowitz AJ, Lunning M, Lynch P, Scheuerman M, Kumar A et al (2016) A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas. Blood 128(22):2991
doi: 10.1182/blood.V128.22.2991.2991